TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Docetaxel and Carboplatin in Treating Women With Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically proven metastatic adenocarcinoma of the breast Measurable disease At least 20 mm in at least 1 dimension Hormone receptor status: Not specified~PATIENT CHARACTERISTICS: Age: 18 and over Sex: Female Menopausal status: Not specified Performance status: ECOG 0-2 Life expectancy: At least 3 months Hematopoietic: Granulocyte count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than upper limit of normal (ULN) SGOT/SGPT no greater than 2.5 times ULN Alkaline phosphatase no greater than ULN OR SGOT/SGPT no greater than ULN Alkaline phosphatase no greater than 4 times ULN Renal: Creatinine no greater than 1.5 times ULN Cardiovascular: No myocardial infarction within the past 6 months No congestive heart failure No unstable angina No clinically significant pericardial effusion or arrhythmia Other: No other invasive malignancy within the past 5 years except curatively treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix No active unresolved infection No prior hypersensitivity reaction to docetaxel No grade 2 or greater sensory or motor neuropathy Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent prophylactic filgrastim (G-CSF) during the first course of study therapy Chemotherapy: No prior chemotherapy for metastatic disease Prior adjuvant chemotherapy allowed More than 1 year since prior paclitaxel, docetaxel, cisplatin, or carboplatin No other concurrent chemotherapy Endocrine therapy: Not specified Radiotherapy: At least 4 weeks since prior radiotherapy to breast, chest wall, or axilla No prior radiotherapy to greater than 30% of bone marrow No concurrent radiotherapy Surgery: At least 4 weeks since prior major surgery and recovered Other: More than 7 days since prior IV antibiotics No concurrent experimental drugs

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- docetaxel + carboplatin (Type: EXPERIMENTAL): This is a multicenter study. Patients receive docetaxel IV over 1 hour and carboplatin IV over 30 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients who achieve stable disease (SD), partial response (PR), or complete response (CR) may receive 4 additional courses past SD, PR, or CR. Patients are followed every 6 months for 2 years and then annually for 3 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vestibular Stimulation in Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must be diagnosed with idiopathic Parkinson's Disease as defined by the UK PDS Brain Bank Criteria.~* Participants must report limitations to Activities of Daily Life (ADL, UPDRS subscale 2)~* Capacity to consent to the study~* Motivated to comply with the protocol~* An understanding of English sufficient to comply with the protocol~* Spouse/ carer willing to support the participant throughout the study~Exclusion Criteria:~* Diagnosis of induced Parkinson's or essential/dystonic tremor~* Premorbid psychiatric history (including affective disorder, psychosis or deliberate self- harm)~* Previous exposure to neurostimulation~* Inner ear pathology

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- Active (Type: ACTIVE_COMPARATOR): Participants will be receiving an active Caloric Vestibular Stimulation treatment for a duration of 8 weeks, 7 days a week, twice daily for 19 minutes.
- Placebo (Type: SHAM_COMPARATOR): Participants will be receiving a Sham Caloric Vestibular Stimulation treatment for a duration of 8 weeks in the same manner as the active arm: 7 days a week, twice daily for 19 minutes.~Individuals allocated to this arm will be later crossed over, in unblinded fashion, to the active arm if the treatment shows evidence of efficacy and safety.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has type 2 diabetes mellitus treated with diet and exercise modification alone or in combination with one oral antidiabetic agent for no longer than 4 years.~Exclusion Criteria:~* Subject has a clinically significant history or presence of any of the following conditions: (a) Hepatic disease, (b) Renal disease, (c) Central nervous system disease, (d) Gastrointestinal disease (e) Pulmonary disease (f) Hematologic disease.~* Subject is currently treated with any of the following excluded medications: (a) Metformin/sulfonylurea combination therapy (b) Thiazolidinediones (c) Insulin as outpatient therapy (d) Regular use of drugs that directly affect gastrointestinal motility (e) Regular use of systemic corticosteroids by oral, intravenous (IV), or intramuscular (IM) route, or potent, inhaled, intrapulmonary, or intranasal steroids known to have a high rate of systemic absorption (f) Regular use of medications with addictive potential such as opiates, narcotics and tranquilizers (g) Antineoplastic agents (h) Transplantation medications (i) Prescription weight-loss medications.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- A1 - Placebo 0.04 mL twice daily (Type: PLACEBO_COMPARATOR): None
- A2 - Placebo 0.04 mL once daily (Type: PLACEBO_COMPARATOR): None
- A3 - Placebo 0.08 mL once daily (Type: PLACEBO_COMPARATOR): None
- B - Exenatide 10 mcg twice daily (Type: EXPERIMENTAL): None
- C - Exenatide 10 mcg once daily (Type: EXPERIMENTAL): None
- D - Exenatide 20 mcg once daily (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female infants born at \>36 weeks of gestation and 2 months of age at the time of consent.~* Healthy infants determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study.~Exclusion Criteria:~* History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis)~* Major known congenital malformation or serious chronic disorder~* Other acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results~* Previous receipt of \>1 dose of hepatitis B vaccine; or receipt of a single hepatitis B vaccine dose administered at \>30 days old, or previous receipt of any licensed or investigational pneumococcal vaccine, or planned receipt through study participation

- Gender: ALL
- Minimum Age: 42 Days
- Maximum Age: 98 Days
- Healthy Volunteers: t

Study Arms:
- 20-valent pneumococcal conjugate vaccine (Type: EXPERIMENTAL): Pneumococcal conjugate vaccine
- 13-valent pneumococcal conjugate vaccine (Type: ACTIVE_COMPARATOR): Pneumococcal conjugate vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment Of Dupuytren's Contracture With Collagenase Clostridium Histolyticum Injection (Xiapex)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Presenting with a Dupuytren's contracture of at least 20 degrees caused by a palpable cord in at least one finger other than the thumb.~* Positive table top test defined as the inability to simultaneously place the affected finger(s) and palm flat against a table top.~Exclusion Criteria:~* Received a treatment on the selected joint, within 90 days of enrollment in the study, for Dupuytren's contracture including needle aponeurotomy or any surgical procedure~* On anticoagulant medication or has received anticoagulant medication (except aspirin less than 150 mg daily) within 7 days before the first injection~* Has a chronic muscular, neurological, or neuromuscular disorder that affects the hands

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Xiapex Injection (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* de novo or secondary acute myeloid leukemia of the FAB subtypes M0-M2 and M4-M7~* de novo or secondary myelodysplastic syndrome FAB subtypes RAEB and RAEB-T~* written informed consent~Exclusion Criteria:~* severe comorbidities~* severe uncontrolled complications of the leukemia~* previous therapy of leukemia/MDS~* HIV-Infection~* known relevant allergy against study medication~* pregnancy~* missing written informed consent

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Efficacy and Safety of Two Doses of Topiramate Compared to Placebo and Propranolol in the Prevention of Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Medical history consistent with migraine with or without aura according to the International Headache Society (IHS) for at least 1 year prior to the study~* Between 3 to 12 migraine periods and no greater than 15 headache days (migraine and non-migraine) per month during the Baseline Phase~* No clinically significant abnormalities on neurological exams, electrocardiogram (ECG) or clinical laboratory test results at baseline~* Female patients must be postmenopausal for at least 1 year, surgically incapable of childbearing, practicing abstinence, or practicing an acceptable method of contraception (requires negative pregnancy test)~Exclusion Criteria:~* Patients with headaches other than migraine~* Patients with episodic tension or sinus headaches~* Onset of migraine after age of 50 years~* Patients who have failed more than two adequate regimens for migraine prophylaxis~* Patients who overuse pain medications or certain other medications

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nitric Oxide During Bypass for Arterial Switch Operation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria;~Each participant must meet all of the following criteria to be enrolled in this study:~* Infant aged greater than or equal to 36 weeks gestation~* Infants less than 2 years~* Diagnosed with TGA and requiring Arterial Switch Operation~* Consent of parents/guardian.~Exclusion criteria~Potential participants will be excluded if they meet any of the following criteria:~* They have multiple major congenital anomalies (anomalies which affect the infant's life expectancy or health status)~* They have multiple other cardiac abnormalities (with the exception of ASD, VSD or PDA)~* They weigh less than 2.2kgs.~* Prior surgical exposure to cardio-pulmonary bypass

- Gender: ALL
- Minimum Age: 0 Days
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention arm (Type: ACTIVE_COMPARATOR): • Intervention arm will receive nitric oxide 20 parts per million (ppm) into the oxygenator of a cardio-pulmonary bypass circuit
- Control arm (Type: NO_INTERVENTION): Control arm will not receive nitric oxide, they will receive standard bypass as per local policy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized, Double-Blind, Placebo-Controlled Study of Oral Milk Immunotherapy for Cow's Milk Allergy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provide signed informed consent (by parent or legal guardian if the subject is a minor) and informed assent if applicable~* Age 6 to 21 years~* Must have history of symptomatic reactivity to cow's milk (eczema, urticaria, upper/lower resp., GI, other associated rash, oral symptoms)~* History of positive skin prick test (wheal \>/= histamine control) or milk-Immunoglobulin E (IgE)\>0.35 kilounits per liter (kU/L)~* Positive DBPCFC~* All females of child bearing age must be using appropriate birth control~Exclusion Criteria:~* History of anaphylaxis requiring hospitalization~* History of intubation related to asthma~* Has the ability to tolerate \>2.4gram of milk protein at initial DBPCFC~* Has a history of allergy to any component of vehicle~* Pregnancy (need negative test)~* Viral upper respiratory infection (URI) or gastroenteritis within 7days of OFC (OFC needs to be rescheduled)~* Has pulmonary function tests \<80% of predicted (FEV1) or clinical history consistent with moderate persistent asthma~* Currently taking greater than medium dose inhaled corticosteroid (\>400mcg/day fluticasone or fluticasone equivalent if \</=12yo or \>600mcg/day if \>12 years old)~* Antihistamine within 1 week prior to skin testing or food challenges (Skin testing and/or food challenge needs to be rescheduled)~* Systemic corticosteroid within 4 weeks prior to baseline visit~* Receiving omalizumab, beta-blocker, Angiotensin-converting enzyme (ACE) inhibitor or tricyclic antidepressant therapy~* Chronic disease (other than asthma, atopic dermatitis, rhinitis) requiring therapy (e.g., heart disease, diabetes)~* Participation in any interventional study for treatment of a food allergy in the past 12 months~* Severe reaction at initial DBPCFC, defined as:~  i. Life-threatening anaphylaxis ii. Requires overnight hospitalization

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Active Treatment (Type: EXPERIMENTAL): Pre-measured doses of dry, nonfat powered milk prepared by the clinical research-registered dieticians
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TeamTRACS Pilot (CTSI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Individuals at least 18 years of age who are members of the multidisciplinary team at the participating CACs.~Exclusion Criteria:~* Under 18 years old

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TeamTRACS (Team Training in Roles, Awareness, Communication, and Support) (Type: EXPERIMENTAL): CACs randomized to the intervention condition (n = 4) will participate in TeamTRACS. CACs will receive an implementation guide to assist in preparing for and maximizing the impact of training.
- Waitlist Comparison (Type: NO_INTERVENTION): CACs randomized to the waitlist comparison (n = 2) will participate in TeamTRACS approximately 4 months after CACs in the intervention condition.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics Study of BAY88-8223 in Japanese Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male ≥ 20 years of age~* Histologically or cytologically confirmed adenocarcinoma of the prostate~* Presents with at least 2 bone metastases, confirmed by scintigraphic imaging within the previous 4 weeks~* Patients who has failed initial hormonal therapy using either an orchiectomy or a Gonadotropin releasing hormone (GnRH) agonist in combination with an antiandrogen must first progress through antiandrogen withdrawal prior to being eligible. The minimum timeframe to document failure of anti-androgen withdrawal will be four weeks~* Progressive castration resistant metastatic disease~* Castrate level of testosterone (\<50 ng/dL), treatment to maintain castrate levels of testosterone must be continued~Exclusion Criteria:~* Has received an investigational drug in the 4 weeks before or is scheduled to receiving one during or in the 8 weeks after study drug administration.~* Has received chemo-, immuno-, or radiotherapy within the last 4 weeks prior to entry in the study, or has not recovered from acute adverse events as a result of such therapy~* Has received prior hemibody external radiotherapy~* Has a need for immediate external radiotherapy~* Has received systemic radiotherapy with radium-223, strontium-89, samarium-153, rhenium-186 or rhenium-188 for the treatment of bony metastases within the last 24 weeks prior to administration of study drug~* When receiving bisphosphonates, has changed the dose within 4 weeks before administration of study drug

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Radium-223 dichloride [50 kBq/kg] (Type: EXPERIMENTAL): None
- Radium-223 dichloride [100 kBq/kg] (Type: EXPERIMENTAL): None
- Radium-223 dichloride [expansion] (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Intravenous Levetiracetam in Neonatal Seizures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Newborns admitted to any of the study sites with electrographic seizures seizures.~2. Term infants gestational age \>36 weeks less than 2 weeks of age.~3. Greater than 2200 grams.~4. Infants for whom parental consent to participate in the study is obtained.~Exclusion Criteria:~1. Infants who are already receiving anticonvulsants~2. If serum creatinine is greater than 1.6mM~3. If seizures are due to correctable metabolic abnormalities (i.e. hypoglycaemia, hypocalcemia, hyponatremia)~4. Subjects in whom death seems imminent, as assessed by the neonatologist.

- Gender: ALL
- Minimum Age: 15 Minutes
- Maximum Age: 14 Days
- Healthy Volunteers: f

Study Arms:
- Intravenous levetiracetam (Type: EXPERIMENTAL): Intravenous levetiracetam 40 to 60 mg/kg loading dose. 10 mg/kg 8 hourly maintenance
- Intravenous phenobarbital (Type: ACTIVE_COMPARATOR): Intravenous phenobarbital 20 to 40 mg/kg load. 1.5 mg/kg 8 hourly maintenance

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: RECOVER:Comparison of Renal Toxicity Between Visipaque(Iodixanol)and Hexabrix(Ioxaglate)in Renal Insufficiency Undergoing Coronary Angiography

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* creatinine clearance rates ≤60 mL/min using the Cockcroft-Gault formula~* Patients who undergo coronary catheterization~* Age of 19 or over 19.~Exclusion Criteria:~* pregnancy~* lactation~* having received contrast media within 7 days of study entry~* emergent coronary angiography~* acute renal failure~* end-stage renal disease requiring dialysis~* history of hypersensitivity reaction to contrast media~* cardiogenic shock~* pulmonary edema~* multiple myeloma~* mechanical ventilation~* parenteral use of diuretics~* use of N-acetylcysteine~* use of metformin or nonsteroidal anti-inflammatory drugs within 48 hours of the procedure.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete